Anti-CD73 therapy impairs tumor angiogenesis

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1466-1473

  Allard, Bertrand ^a   Turcotte, Martin ^a   Spring, Kathleen ^a   Pommey, Sandra ^a   Royal, Isabelle ^a,b   Stagg, John ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

adenosine; cancer therapy; CD73; tumor angiogenesis

Indexed keywords

5' NUCLEOTIDASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD73; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VASCULARIZATION;

EID: 84891824680     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28456     Document Type: Article

References (48)

1. Beavis PA, Stagg J, Darcy PK, et al. CD73: a potent suppressor of antitumor immune responses. Trend Immunol 2012; 33: 231-7.
2. Allard B, Turcotte M, Stagg J,. CD73-Generated Adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J BiomedBiotechnol 2012; 2012: 1-8.
3. Synnestvedt K, Furuta GT, Comerford KM, et al. Ecto-5?-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110: 993-1002.
4. Kobayashi S, Zimmermann H, Millhorn DE,. Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. J Neurochem 2000; 74: 621-32.
5. Spychala J, Lazarowski E, Ostapkowicz A, et al. Role of estrogen receptor in the regulation of ecto-5′-nucleotidase and adenosine in breast cancer. Clin Cancer Res 2004; 10: 708-17.
6. Wang H, Lee S, Nigro CL, et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer 2012; 106: 1446-52.
7. Lo Nigro C, Monteverde M, Lee S, et al. NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer 2012; 107: 75-83.
8. Huang S, Apasov S, Koshiba M, et al. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997; 90: 1600-10.
9. Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. PNAS 2006; 103: 13132-7.
10. Sitkovsky MV, Kjaergaard J, Lukashev D, et al. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008; 14: 5947-52.
11. Blay J, White TD, Hoskin DW,. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 1997; 57: 2602-5.
12. Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. PNAS 2010; 107: 1547-52.
13. Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011; 71: 2892-900.
14. Stagg J, Beavis PA, Divisekera U, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012; 72: 2190-6.
15. Wang L, Fan J, Thompson LF, et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011; 121: 2371-82.
16. Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 2010; 70: 2245-55.
17. Motz GT, Coukos G,. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011; 11: 702-11.
18. Chouaib S, Messai Y, Couve S, et al. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 2012: 3: 21.
19. Eltzschig HK,. Extracellular adenosine signaling in molecular medicine. J Mol Med 2013; 91: 141-6.
20. Colgan SP, Eltzschig HK,. Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery. Ann Rev Physiol 2012; 74: 153-75.
21. Eltzschig HK, Thompson LF, Karhausen J, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 2004; 104: 3986-92.
22. Kong T, Westerman KA, Faigle M, et al. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 2006; 20: 2242-50.
23. Smits P, Williams SB, Lipson DE, et al. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 1995; 92: 2135-41.
24. Montesinos MC, Shaw JP, Yee H, et al. Adenosine A2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am J Pathol 2004; 164: 1887-92.
25. Feoktistov I, Goldstein AE, Ryzhov S, et al. Differential expression of adenosine receptors in human endothelial cells role of A2B receptors in angiogenic factor regulation. Circul Res 2002; 90: 531-8.
26. Feoktistov I, Ryzhov S, Zhong H, et al. Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension 2004; 44: 649-54.
27. Zimmermann H,. Two novel families of ectonucleotidases: molecular structures, catalytic properties and a search for function. Trends Pharmacol Sci 1999; 20: 231-6.
28. Cass CE, Young JD, Baldwin SA, et al. Nucleoside transporters of mammalian cells. Pharm Biotechnol 1999; 12: 313-52.
29. Donaldson SH, Picher M, Boucher RC,. Secreted and cell-associated adenylate kinase and nucleoside diphosphokinase contribute to extracellular nucleotide metabolism on human airway surfaces. Am J Respir Cell Mol Biol 2002; 26: 209-15.
30. Thompson LF, Eltzschig HK, Ibla JC, et al. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 2004; 200: 1395-405.
31. Eckle T, Krahn T, Grenz A, et al. Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007; 115: 1581-90.
32. Böring YC, Flögel U, Jacoby C, et al. Lack of ecto-5′-nucleotidase (CD73) promotes arteriogenesis. Cardiovasc Res 2013; 97: 88-96.
33. Sadej R, Skladanowski AC,. Dual, enzymatic and non-enzymatic, function of ecto-5′-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim Pol 2011; 59: 647-52.
34. Sadej R, Inai K, Rajfur Z, et al. Tenascin C interacts with ecto-5′-nucleotidase (eN) and regulates adenosine generation in cancer cells. Biochim Biophys Acta 2008; 1782: 35-40.
35. Andrade CMB, Lopez PLC, Noronha BT, et al. Ecto-5′-nucleotidase/ CD73 knockdown increases cell migration and mRNA level of collagen I in a hepatic stellate cell line. Cell Tissue Res 2011; 344: 279-86.
36. Airas L, Hellman J, Salmi M, et al. CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. J Exp Med 1995; 182: 1603-8.
37. Airas L, Jalkanen S,. CD73 mediates adhesion of B cells to follicular dendritic cells. Blood 1996; 88: 1755-64.
38. Mitra SK, Mikolon D, Molina JE, et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006; 25: 5969-84.
39. Arnaoutova I, Kleinman HK,. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protocols 2010; 5: 628-35.
40. Liang C-C, Park AY, Guan J-L,. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protocols 2007; 2: 329-33.
41. Stagg J, Smyth MJ,. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010; 29: 5346-58.
42. Wang L, Tang S, Wang Y, et al. Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis. Clin Exp Metastasis 2013; 30: 671-80.
43. Ryzhov S, Novitskiy SV, Zaynagetdinov R, et al. Host A2B adenosine receptors promote carcinoma growth. Neoplasia 2008; 10: 987-95.
44. Desai A, Victor-Vega C, Gadangi S, et al. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol Pharmacol 2005; 67: 1406-13.
45. Ahmad A, Ahmad S, Glover L, et al. Adenosine A2A receptor is a unique angiogenic target of HIF-2α in pulmonary endothelial cells. PNAS 2009; 106: 10684-9.
46. Grant MB, Davis MI, Caballero S, et al. Proliferation, migration, and ERK activation in human retinal endothelial cells through A2B adenosine receptor stimulation. IOVS 2001; 42: 2068-73.
47. Loi S, Pommey S, Haibe-Kains B, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A. 2013; 110: 11091-6.
48. Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109: 17561-6.